CUBICIN RF's oppositions filed in EPO
CUBICIN RF Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(6 years from now) | |
Cubicin Rf is owned by Cubist Pharms Llc.
Cubicin Rf contains Daptomycin.
Cubicin Rf has a total of 1 drug patent out of which 0 drug patents have expired.
Cubicin Rf was authorised for market use on 12 September, 2003.
Cubicin Rf is available in powder;intravenous dosage forms.
The generics of Cubicin Rf are possible to be released after 23 November, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-211) | Sep 01, 2020 |
| New Patient Population(NPP) | Mar 29, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Treatment: NA
Dosage: POWDER;INTRAVENOUS
How can I launch a generic of CUBICIN RF before it's drug patent expiration?
More Information on Dosage
CUBICIN RF family patents
